Yi Lin

List of Publications by Year
in descending order

155 papers	21,690 citations	34105 52 h-index	10158 140 g-index
157 all docs	157 docs citations	157 times ranked	19014 citing authors

#	Article	IF	Citations
1	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 2531-2544.	27.0	3,865
2	Chimeric antigen receptor T-cell therapy â€" assessment and management of toxicities. Nature Reviews Clinical Oncology, 2018, 15, 47-62.	27.6	1,659
3	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1â€"2 trial. Lancet Oncology, The, 2019, 20, 31-42.	10.7	1,467
4	Origins of circulating endothelial cells and endothelial outgrowth from blood. Journal of Clinical Investigation, 2000, 105, 71-77.	8.2	1,370
5	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 2019, 380, 1726-1737.	27.0	1,130
6	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine, 2021, 384, 705-716.	27.0	1,129
7	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet, The, 2021, 398, 314-324.	13.7	711
8	Structure of FUS Protein Fibrils and Its Relevance to Self-Assembly and Phase Separation of Low-Complexity Domains. Cell, 2017, 171, 615-627.e16.	28.9	605
9	Circulating Activated Endothelial Cells in Sickle Cell Anemia. New England Journal of Medicine, 1997, 337, 1584-1590.	27.0	593
10	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology, 2020, 38, 3119-3128.	1.6	481
11	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clinic Proceedings, 2013, 88, 360-376.	3.0	440
12	Toxic PR Poly-Dipeptides Encoded by the C9orf72 Repeat Expansion Target LC Domain Polymers. Cell, 2016, 167, 789-802.e12.	28.9	363
13	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood, 2017, 129, 3419-3427.	1.4	335
14	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, The, 2021, 398, 491-502.	13.7	315
15	The LC Domain of hnRNPA2 Adopts Similar Conformations in Hydrogel Polymers, Liquid-like Droplets, and Nuclei. Cell, 2015, 163, 829-839.	28.9	262
16	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood, 2017, 129, 2111-2119.	1.4	249
17	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 4898-4911.	5.2	238
18	Immunosuppressive $CD14^{+}HLA$–$DR^{low/−}$ monocytes in prostate cancer. Prostate, 2010, 70, 443-455.	2.3	233

#	Article	IF	Citations
19	Immunosuppressive CD14+HLA-DRlow/â˜ monocytes in B-cell non-Hodgkin lymphoma. Blood, 2011, 117, 872-881.	1.4	218
20	Toxic PR _n poly-dipeptides encoded by the <i>C9orf72</i> repeat expansion block nuclear import and export. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1111-E1117.	7.1	202
21	Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology, 2010, 12, 351-365.	1.2	197
22	Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro-Oncology, 2010, 12, 631-644.	1.2	194
23	Coexistent Multiple Myeloma or Increased Bone Marrow Plasma Cells Define Equally High-Risk Populations in Patients With Immunoglobulin Light Chain Amyloidosis. Journal of Clinical Oncology, 2013, 31, 4319-4324.	1.6	193
24	Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model. Clinical Cancer Research, 2009, 15, 7246-7255.	7.0	176
25	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018, 8, 59.	6.2	171
26	Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood, 2002, 99, 457-462.	1.4	162
27	Ciltacabtagene Autoleucel, an Antiâ€"B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. Journal of Clinical Oncology, 2023, 41, 1265-1274.	1.6	160
28	Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology, 2013, 31, 4529-4535.	1.6	147
29	IAP antagonists induce anti-tumor immunity in multiple myeloma. Nature Medicine, 2016, 22, 1411-1420.	30.7	133
30	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
31	Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings, 2017, 92, 578-598.	3.0	115
32	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature Reviews Clinical Oncology, 2018, 15, 218-218.	27.6	114
33	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nature Medicine, 2022, 28, 735-742.	30.7	114
34	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
35	A Method for Identification and Analysis of Non-Overlapping Myeloid Immunophenotypes in Humans. PLoS ONE, 2015, 10, e0121546.	2.5	100
36	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood, 2021, 138, 11-22.	1.4	90

#	Article	IF	Citations
37	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma. British Journal of Haematology, 2021, 194, 690-700.	2.5	88
38	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplantation, 2019, 54, 353-367.	2.4	81
39	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. American Journal of Hematology, 2015, 90, 181-186.	4.1	76
40	Outcomes of patients with renal monoclonal immunoglobulin deposition disease. American Journal of Hematology, 2016, 91, 1123-1128.	4.1	76
41	Outcomes of patients with POEMS syndrome treated initially with radiation. Blood, 2013, 122, 68-73.	1.4	74
42	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. Mayo Clinic Proceedings, 2017, 92, 908-917.	3.0	72
43	N‐terminal fragment of the type‐B natriuretic peptide (NT‐proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. American Journal of Hematology, 2016, 91, 1129-1134.	4.1	71
44	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
45	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	7.2	64
46	Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer Journal, 2018, 8, 116.	6.2	64
47	Clinical Application of Mesenchymal Stem Cells in the Treatment and Prevention of Graft-versus-Host Disease. Advances in Hematology, 2011, 2011, 1-17.	1.0	59
48	Immunosuppressive CD14^{+}HLA-DR$^{lo/neg}$ monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes. OncoImmunology, 2017, 6, e1252013.	4.6	59
49	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry‐Verified Typing. Mayo Clinic Proceedings, 2019, 94, 472-483.	3.0	59
50	Association of an increased frequency of CD14^{+}HLA‐DR$^{lo/neg}$ monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). British Journal of Haematology, 2012, 156, 674-676.	2.5	58
51	Cell Damage in Light Chain Amyloidosis. Journal of Biological Chemistry, 2016, 291, 19813-19825.	3.4	58
52	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	5.2	58
53	Long‐term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. American Journal of Hematology, 2016, 91, 585-589.	4.1	57
54	*MYD88* mutation status does not impact overall survival in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57

#	Article	IF	Citations
55	Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses. Frontiers in Immunology, 2014, 5, 147.	4.8	55
56	Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen. American Journal of Roentgenology, 2016, 206, 655-659.	2.2	54
57	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood, 2017, 130, 1198-1204.	1.4	54
58	Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy inÂmultiple myeloma. Blood, 2022, 139, 3708-3721.	1.4	53
59	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. Circulation: Cardiovascular Imaging, 2018, 11, e006588.	2.6	51
60	Immune monitoring using the predictive power of immune profiles. , 2013, 1, 7.		50
61	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood, 2017, 129, 82-87.	1.4	50
62	Clinical heterogeneity of diffuse large B cell lymphoma following failure of frontâ€line immunochemotherapy. British Journal of Haematology, 2017, 179, 50-60.	2.5	49
63	Efficacy of VDT PACEâ€like regimens in treatment of relapsed/refractory multiple myeloma. American Journal of Hematology, 2018, 93, 179-186.	4.1	49
64	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. Blood, 2021, 137, 1832-1835.	1.4	48
65	Induction therapy preâ€autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. American Journal of Hematology, 2016, 91, 984-988.	4.1	45
66	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Annals of Medicine, 2017, 49, 545-551.	3.8	45
67	Redox-mediated regulation of an evolutionarily conserved cross-Î² structure formed by the TDP43 low complexity domain. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28727-28734.	7.1	44
68	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer Journal, 2021, 11, 116.	6.2	44
69	Systemic Immunoglobulin Light Chain Amyloidosisâ€"Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clinic Proceedings, 2016, 91, 1354-1361.	3.0	43
70	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia, 2022, 36, 801-808.	7.2	43
71	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances, 2021, 5, 4149-4155.	5.2	42
72	Betaâ€blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. American Journal of Hematology, 2017, 92, 50-55.	4.1	41

#	Article	IF	Citations
73	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41
74	Tenâ€year survivors in AL amyloidosis: characteristics and treatment pattern. British Journal of Haematology, 2019, 187, 588-594.	2.5	40
75	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. European Heart Journal, 2022, 43, 1928-1940.	2.2	39
76	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
77	Enhancing the Râ€ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. American Journal of Hematology, 2020, 95, 310-315.	4.1	37
78	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. Leukemia, 2019, 33, 527-531.	7.2	36
79	Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma. American Journal of Hematology, 2013, 88, 375-378.	4.1	34
80	Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 4224-4233.	7.0	33
81	Impact of MYD88[L265P] mutation status on histological transformation of Waldenström Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
82	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. American Journal of Hematology, 2014, 89, 1051-1054.	4.1	32
83	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	7.0	32
84	Transiently structured head domains control intermediate filament assembly. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	32
85	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clinic Proceedings, 2021, 96, 1546-1577.	3.0	32
86	Immunotherapy of lymphomas. Journal of Clinical Investigation, 2020, 130, 1576-1585.	8.2	32
87	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 2020, 58, 58-64.	2.2	31
88	Clinical characteristics and outcomes in biclonal gammopathies. American Journal of Hematology, 2016, 91, 473-475.	4.1	30
89	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	6.2	30
90	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. Blood Cancer Journal, 2018, 8, 125.	6.2	29

#	Article	IF	Citations
91	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2020, 34, 1135-1143.	7.2	29
92	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28
93	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
94	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 326-335.	0.4	27
95	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. Radiotherapy and Oncology, 2022, 166, 171-179.	0.6	27
96	HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. OncoImmunology, 2020, 9, 1744947.	4.6	26
97	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. Nephrology Dialysis Transplantation, 2016, 31, 1284-1289.	0.7	25
98	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
99	Efficacy of daratumumab‐based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. American Journal of Hematology, 2017, 92, 1146-1155.	4.1	25
100	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 13-16.	3.0	25
101	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, 50.	6.2	25
102	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. American Journal of Hematology, 2018, 93, 1384-1393.	4.1	24
103	Comparative analysis of staging systems in AL amyloidosis. Leukemia, 2019, 33, 811-814.	7.2	22
104	Implications of detecting serum monoclonal protein by MASS‐fix following stem cell transplantation in multiple myeloma. British Journal of Haematology, 2021, 193, 380-385.	2.5	21
105	Cross-β polymerization and hydrogel formation by low-complexity sequence proteins. Methods, 2017, 126, 3-11.	3.8	19
106	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. American Journal of Hematology, 2015, 90, 888-891.	4.1	18
107	Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer Journal, 2018, 8, 70.	6.2	18
108	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. Blood Cancer Journal, 2020, 10, 4.	6.2	18

#	Article	IF	Citations
109	Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells. Leukemia, 2020, 34, 1383-1393.	7.2	17
110	Systematic Review of Risk factors and Incidence of Acute Kidney Injury Among Patients Treated with CAR-T Cell Therapies. Kidney International Reports, 2021, 6, 1416-1422.	0.8	17
111	Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. Journal of Hematology and Oncology, 2022, 15, 36.	17.0	17
112	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in Bâ€•and Tâ€cell nonâ€‹<scp>H</scp>odgkin lymphoma. American Journal of Hematology, 2014, 89, 1116-1120.	4.1	16
113	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. American Journal of Hematology, 2017, 92, 435-440.	4.1	16
114	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	3.0	16
115	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. Journal of Internal Medicine, 2017, 281, 611-619.	6.0	15
116	Elevation of serum lactate dehydrogenase in <scp>AL</scp> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. British Journal of Haematology, 2017, 178, 888-895.	2.5	15
117	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. American Journal of Hematology, 2019, 94, 751-756.	4.1	15
118	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor <scp>T</scp>â€cell therapy. American Journal of Hematology, 2021, 96, E399-E402.	4.1	14
119	Phase separation in RNA biology. Journal of Genetics and Genomics, 2021, 48, 872-880.	3.9	14
120	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Advances, 2021, 5, 2753-2759.	5.2	13
121	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. Critical Care Medicine, 2022, 50, 81-92.	0.9	13
122	Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement. Mayo Clinic Proceedings, 2019, 94, 2361-2364.	3.0	12
123	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. American Journal of Hematology, 2020, 95, 637-642.	4.1	12
124	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. Annals of Hematology, 2021, 100, 2529-2539.	1.8	12
125	Strategies for improving the reporting of human immunophenotypes by flow cytometry. , 2014, 2, 18.		11
126	ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplantation and Cellular Therapy, 2022, 28, 284-293.	1.2	11

#	Article	IF	Citations
127	Immune independent crosstalk between lymphoma and myeloid suppressor CD14^{+}HLA-DR$^{low/neg}$monocytes mediates chemotherapy resistance. OncoImmunology, 2015, 4, e996470.	4.6	10
128	Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagulation and Fibrinolysis, 2016, 27, 101-108.	1.0	9
129	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. Haematologica, 2016, 101, 1102-1109.	3.5	9
130	Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage. Cytotherapy, 2017, 19, 1426-1437.	0.7	9
131	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	5.2	9
132	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 451-460.e2.	0.4	9
133	The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. Blood Cancer Journal, 2021, 11, 124.	6.2	9
134	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. Current Treatment Options in Oncology, 2022, 23, 171-187.	3.0	9
135	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	7.2	8
136	Outcomes in primary cutaneous diffuse large B‑cell lymphoma, leg type. Hematological Oncology, 2021, 39, 658-663.	1.7	8
137	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. American Journal of Hematology, 2021, 96, 446-454.	4.1	8
138	Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. American Journal of Hematology, 2021, 96, E427-E430.	4.1	7
139	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	4.1	6
140	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). Blood Cancer Journal, 2022, 12, 62.	6.2	6
141	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. American Journal of Hematology, 2017, 92, E507-E512.	4.1	5
142	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. American Journal of Hematology, 2022, , .	4.1	5
143	Disseminated Histoplasmosis: A Cause of Hemophagocytic Syndrome. Mayo Clinic Proceedings, 2013, 88, e123.	3.0	4
144	Long‑term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. American Journal of Hematology, 2014, 89, 302-305.	4.1	4

#	Article	IF	Citations
145	Lines of therapy before autologous stem cell transplant and <scp>CAR‑T</scp> affect outcomes in aggressive <scp>Non‑Hodgkin's</scp> lymphoma. American Journal of Hematology, 2021, 96, E386-E389.	4.1	4
146	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. Leukemia and Lymphoma, 2022, 63, 1363-1368.	1.3	4
147	Serum free light chain measurements to reduce 24‑h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. American Journal of Hematology, 2018, 93, 1207-1210.	4.1	3
148	Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma. Blood Cancer Journal, 2020, 10, 95.	6.2	3
149	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B‑cell lymphoma treated with axicabtagene ciloleucel. European Journal of Haematology, 2021, 107, 48-53.	2.2	3
150	68-Year-Old Man With Fatigue, Fever, and Weight Loss. Mayo Clinic Proceedings, 2005, 80, 939-942.	3.0	2
151	Predictors of short-term survival in Waldenström Macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 2975-2979.	1.3	2
152	Peak absolute lymphocyte count after <scp>CAR‑T</scp> infusion predicts clinical response in aggressive lymphoma. American Journal of Hematology, 2022, 97, .	4.1	2
153	Pulmonary Valve Replacement With Balloon-Expandable Prosthesis Under Direct Vision: A Novel Therapeutic Approach. Annals of Thoracic Surgery, 2016, 101, 1576-1577.	1.3	1
154	The role of phosphatase and tensin homolog deleted on chromosome 10 and focal adhesion kinase in aggressive multiple myeloma. Leukemia and Lymphoma, 2012, 53, 1021-1022.	1.3	0
155	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncology Practice, 2022, , OP2100789.	2.9	0